New chemo cocktail aims to boost stem cell transplant success in blood cancers
NCT ID NCT02250937
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This phase 2 trial tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can improve outcomes for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The study enrolls 116 adults aged 18-70 who have a matched donor. The goal is to see if this approach helps destroy cancer cells more effectively and leads to longer survival without the disease returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (venetoclax, busulfan, cladribine, fludarabine) followed by donor stem cell transplant
What this could lead to
If successful, this approach could improve long-term survival and reduce relapse for people with AML or MDS undergoing a donor stem cell transplant.
What could go wrong
This is a mid-stage trial with only 116 participants, so results may not apply to everyone. The intense chemo regimen carries risks like infection, organ damage, and graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.